Market Overview

Morgan Stanley Sees Sapien Becoming Leading Product Line for Edwards Lifesciences

Share:
Related EW
JPMorgan: Time To Buy Edwards Lifesciences
Oppenheimer: 3 Healthcare Stocks And 2 Energy Stocks To Buy Now
Edwards Valve Stumble Makes Tiara Sparkle (Seeking Alpha)

In a report published Friday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Edwards Lifesciences (NYSE: EW).

In the report, Morgan Stanley noted, “Sapien should prove to be the leading product line in transcatheter valves into '14 and beyond, supported by clinical data. The TAVR market is likely to continue its expansion, supported by better budgets in Europe, favorable clinical data in lower risk populations, and more deliverable products. A mitral replacement program could drive upside given the larger potential patient pool relative to the aortic space. Higher valve revenue mix supports higher GMs.”

Edwards Lifesciences closed on Thursday at $80.27.

Latest Ratings for EW

DateFirmActionFromTo
May 2015JP MorganUpgradesNeutralOverweight
Apr 2015BarclaysMaintainsEqual-weight
Dec 2014BarclaysMaintainsEqual-weight

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (EW)

Around the Web, We're Loving...